Bories Mathilde, Bouzillé Guillaume, Cuggia Marc, Le Corre Pascal
Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France.
Univ Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, F-35000 Rennes, France.
Pharmaceutics. 2021 Feb 16;13(2):266. doi: 10.3390/pharmaceutics13020266.
Drug-drug interactions (DDI) occurring with potentially inappropriate medications (PIM) are additional risk factors that may increase the inappropriate character of PIM. The aim of this study was (1) to describe the prevalence and severity of DDI in patients with PIM and (2) to evaluate the DDI specifically regarding PIM. This systematic review is based on a search carried out on PubMed and Web-of-Science from inception to June 30, 2020. We extracted data of original studies that assessed the prevalence of both DDI and PIM in elderly patients in primary care, nursing home and hospital settings. Four hundred and forty unique studies were identified: 91 were included in the qualitative analysis and 66 were included in the quantitative analysis. The prevalence of PIM in primary care, nursing home and hospital were 19.1% (95% confidence intervals (CI): 15.1-23.0%), 29.7% (95% CI: 27.8-31.6%) and 44.6% (95% CI: 28.3-60.9%), respectively. Clinically significant severe risk-rated DDI averaged 28.9% (95% CI: 17.2-40.6), in a hospital setting; and were approximately 7-to-9 lower in primary care and nursing home, respectively. Surprisingly, only four of these studies investigated DDI involving specifically PIM. Hence, given the high prevalence of severe DDI in patients with PIM, further investigations should be carried out on DDI involving specifically PIM which may increase their inappropriate character, and the risk of adverse drug reactions.
与潜在不适当用药(PIM)相关的药物相互作用(DDI)是可能增加PIM不适当性的额外风险因素。本研究的目的是:(1)描述PIM患者中DDI的发生率和严重程度;(2)具体评估与PIM相关的DDI。本系统评价基于对PubMed和Web of Science从创刊至2020年6月30日进行的检索。我们提取了评估初级保健、疗养院和医院环境中老年患者DDI和PIM发生率的原始研究数据。共识别出440项独特研究:91项纳入定性分析,66项纳入定量分析。初级保健、疗养院和医院中PIM的发生率分别为19.1%(95%置信区间(CI):15.1 - 23.0%)、29.7%(95%CI:27.8 - 31.6%)和44.6%(95%CI:28.3 - 60.9%)。在医院环境中,具有临床显著严重风险等级的DDI平均为28.9%(95%CI:17.2 - 40.6);在初级保健和疗养院中分别低约7至9个百分点。令人惊讶的是,这些研究中只有四项专门调查了涉及PIM的DDI。因此,鉴于PIM患者中严重DDI的高发生率,应进一步开展关于专门涉及PIM的DDI的研究,因为这可能会增加其不适当性以及药物不良反应的风险。